ECSP12011996A - Moduladores de crth2 - Google Patents

Moduladores de crth2

Info

Publication number
ECSP12011996A
ECSP12011996A ECSP12011996A ECSP12011996A EC SP12011996 A ECSP12011996 A EC SP12011996A EC SP12011996 A ECSP12011996 A EC SP12011996A EC SP12011996 A ECSP12011996 A EC SP12011996A
Authority
EC
Ecuador
Prior art keywords
crth2
modulators
crth2 modulators
disorders
useful
Prior art date
Application number
Other languages
English (en)
Inventor
Kevin T Sprott
Joel D Moore
Bo Peng
Charles Kim
Ara Mermerian
Takashi Nakai
Colleen Hudson
Jason Rohde
Regina Graul
James Jia
Wilmin Bartolini
Original Assignee
Ironwoodpharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwoodpharmaceuticals Inc filed Critical Ironwoodpharmaceuticals Inc
Publication of ECSP12011996A publication Critical patent/ECSP12011996A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Se divulgan los moduladores de CRTH2, particularmente los antagonistas de CRTH2, que son útiles para tratar varios trastornos, incluyendo el asma y los trastornos respiratorios.Los compuestos pertenecen al género descrito por la fórmula I.
ECSP12011996 2009-12-23 2012-06-22 Moduladores de crth2 ECSP12011996A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28984109P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
ECSP12011996A true ECSP12011996A (es) 2012-10-30

Family

ID=43735997

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011996 ECSP12011996A (es) 2009-12-23 2012-06-22 Moduladores de crth2

Country Status (21)

Country Link
US (1) US8674115B2 (es)
EP (1) EP2516416A1 (es)
JP (1) JP5731538B2 (es)
KR (1) KR20120098908A (es)
CN (1) CN102822163B (es)
AR (1) AR079492A1 (es)
AU (1) AU2010333829A1 (es)
BR (1) BR112012017756A2 (es)
CA (1) CA2785191A1 (es)
CL (1) CL2012001712A1 (es)
CO (1) CO6640201A2 (es)
CR (1) CR20120343A (es)
EA (1) EA201200855A1 (es)
EC (1) ECSP12011996A (es)
MX (1) MX2012007239A (es)
PH (1) PH12012501280A1 (es)
SG (1) SG181900A1 (es)
TW (1) TW201130810A (es)
UY (1) UY33110A (es)
WO (1) WO2011079007A1 (es)
ZA (1) ZA201204527B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078210A1 (en) * 2010-12-08 2012-06-14 Ironwood Pharmaceuticals, Inc. Crth2 modulators and preparation thereof
JP5999387B2 (ja) * 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｒｔｈ２拮抗薬としてのピラゾール化合物
US20150080381A1 (en) * 2012-04-12 2015-03-19 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
WO2017104728A1 (ja) * 2015-12-16 2017-06-22 国立大学法人東京大学 食物アレルギー治療薬
ES2791319T3 (es) * 2016-04-22 2020-11-03 Astrazeneca Ab Inhibidores de MCL1 macrocíclicos para tratar el cáncer
WO2021209473A1 (en) * 2020-04-16 2021-10-21 F. Hoffmann-La Roche Ag Biphenyl derivatives

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
EP0192963B1 (de) 1985-02-27 1988-07-20 Werkzeugmaschinenfabrik Oerlikon-Bührle AG Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
MX9205392A (es) * 1991-10-29 1993-04-01 Du Pont Triazolcarbozamidas herbicidas y procedimiento para su obtencion.
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
CN1134411C (zh) 1995-06-21 2004-01-14 盐野义制药株式会社 双环氨基衍生物及含有此类化合物的前列腺素d2拮抗剂
US5859042A (en) * 1995-09-27 1999-01-12 Ono Pharmaceutical Co., Ltd. Five membered heterocyclic compounds
EP0945450B1 (en) 1996-12-12 2005-05-11 Shionogi & Co., Ltd. Fused heterocyclic benzenecarboxylic acid amide derivatives and pgd2 antagonists containing the same
PL191760B1 (pl) 1996-12-13 2006-06-30 Shionogi & Co Związki, pochodne benzotiofenokarboksyamidu, związki pośrednie, kompozycja farmaceutyczna zawierająca te pochodne oraz lek do leczenia blokady nosa
PT1140012E (pt) 1998-12-17 2004-05-31 Alza Corp Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US20010051624A1 (en) 2000-04-12 2001-12-13 Jones Thomas R. Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists
ATE311200T1 (de) 2000-04-12 2005-12-15 Merck Frosst Canada Inc Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EP1368354A1 (en) 2001-03-07 2003-12-10 Pfizer Products Inc. Modulators of chemokine receptor activity
EP1424325A4 (en) 2001-09-07 2005-12-21 Ono Pharmaceutical Co INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT
CA2459515A1 (en) 2001-09-07 2003-03-20 Kazuhiko Torisu Indole derivatives
OA12670A (en) 2001-10-22 2006-06-20 Pfizer Prod Inc Piperazine derivatives with ccr1 receptor antagonist activity.
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
PL372968A1 (en) 2002-04-08 2005-08-08 Pfizer Inc. Tropane derivatives as ccr5 modulators
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
WO2003097042A1 (en) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Pgd2 receptor antagonist
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
WO2004014875A1 (en) 2002-08-12 2004-02-19 Pfizer Products Inc. Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
WO2004018435A1 (en) 2002-08-24 2004-03-04 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
WO2004032848A2 (en) 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20040092529A1 (en) 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
US20040097554A1 (en) 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040116441A1 (en) 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
SE0203820D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab chemical compounds
AR042628A1 (es) 2002-12-20 2005-06-29 Astrazeneca Ab Derivados de piperidina como moduladores del receptor ccr5
PL377314A1 (pl) * 2002-12-20 2006-01-23 Amgen Inc. Modulatory astmy i zapaleń na tle alergicznym
SE0203828D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab Chemical compounds
BRPI0413363A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
US20090105218A1 (en) * 2004-05-29 2009-04-23 7Tm Pharma A/S CRTH2 Receptor Ligands For Therapeutic Use
EP1758579A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
EP1758874A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Substituted thiazoleacetic acids as crth2 ligands
CN1980664B (zh) 2004-05-29 2011-02-23 7Tm制药联合股份有限公司 用于医学用途的crth2受体配体
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
CA2658496A1 (en) * 2006-07-22 2008-01-31 Oxagen Limited 2-{5-fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1h-indol-yl} acetic acid derivatives and esters thereof having crth2 antagonist activity
JP2011509991A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
WO2009102462A1 (en) * 2008-02-15 2009-08-20 Abbott Laboratories Thienopyrroles and pyrrolothiazoles as new therapeutic agents

Also Published As

Publication number Publication date
CL2012001712A1 (es) 2012-12-07
CN102822163B (zh) 2016-01-20
JP5731538B2 (ja) 2015-06-10
CA2785191A1 (en) 2011-06-30
KR20120098908A (ko) 2012-09-05
US8674115B2 (en) 2014-03-18
BR112012017756A2 (pt) 2016-04-19
CO6640201A2 (es) 2013-03-22
AU2010333829A1 (en) 2012-07-12
AR079492A1 (es) 2012-02-01
WO2011079007A1 (en) 2011-06-30
ZA201204527B (en) 2013-09-25
UY33110A (es) 2011-07-29
TW201130810A (en) 2011-09-16
US20110150834A1 (en) 2011-06-23
JP2013515726A (ja) 2013-05-09
CN102822163A (zh) 2012-12-12
EA201200855A1 (ru) 2013-04-30
EP2516416A1 (en) 2012-10-31
CR20120343A (es) 2013-01-25
PH12012501280A1 (en) 2013-02-04
SG181900A1 (en) 2012-08-30
MX2012007239A (es) 2012-10-15

Similar Documents

Publication Publication Date Title
UY33735A (es) Compuestos antivirales
MX388468B (es) Compuestos multicíclicos y métodos de uso de los mismos.
ECSP11011439A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
MX2019003738A (es) Compuestos antivirales.
CR11861A (es) Compuestos organicos
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
DOP2012000263A (es) Compuestos quimicos
UY33750A (es) ?Compuestos insecticidas aromáticos derivados de bisamida, procesos e intermediarios para prepararlos y composiciones que los usan.?
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
ECSP11011347A (es) Nicotinamida sustituida como moduladores KCNQ2/3
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
CR20120264A (es) Compuestos
ECSP11011244A (es) Nuevos herbicidas.
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
CR20120204A (es) Nuevo uso antitumoral de cabazitaxel
CR20140218A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas iii
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
CR20120343A (es) Moduladores de crth2
CO6410291A2 (es) 3-amino-2-mercaptoquinolina sustituidacomo modulador de kcnq2/3
BR112013028368A2 (pt) novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona
UY34407A (es) Nuevos moduladores de trpv3
CL2012003539A1 (es) Compuestos derivados de alquil-piperazino-fenil 4(3h)ona; composicion farmaceutica y su uso para el tratamiento de los trastornos asociados a los receptores serotoninergicos 5-ht1a y 5-ht2a, tales como depresion, ansiedad, y trastornos del sueño.
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75